Posted by Michael Wonder on 13 Feb 2019
Mylan launches Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder), at a list price 70% less than the brand
12 February 2019 - Unique pricing of Wixela Inhub immediately benefits patients and reduces overall cost to the U.S. health care system.
Mylan today announced the launch of the first FDA approved therapeutically equivalent, substitutable generic of Advair Diskus, Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), approved by the U.S. FDA through the abbreviated new drug application pathway. Wixela Inhub is indicated for certain patients with asthma or chronic obstructive pulmonary disease.
All three strengths of Wixela Inhub will be offered at a wholesale acquisition cost 70% less than Advair Diskus and 67% less than GSK's authorised generic version which launched on 8 February. The wholesale acquisition costs of Wixela Inhub 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths are $93.71, $116.44 and $153.14, respectively.
